Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors

Patients with relapsed and refractory multiple myeloma have a poor prognosis. The mitogen-activated protein kinase (MAPK) pathway has been implicated in the pathogenesis of multiple myeloma. Several mutations in this pathway can lead to its constitutive activation leading to oncogenesis. One such mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Otieno, Steve Biko, Nasir, Syed, Weir, Alva, Johnson, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748897/
https://www.ncbi.nlm.nih.gov/pubmed/33381330
http://dx.doi.org/10.1155/2020/8821415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748897/
https://www.ncbi.nlm.nih.gov/pubmed/33381330
http://dx.doi.org/10.1155/2020/8821415

Ejemplares similares